Intron A (Schering Corp) en es it fr

Intron A (Schering Corp) Brand names, Intron A (Schering Corp) Analogs

Intron A (Schering Corp) Brand Names Mixture

  • No information avaliable

Intron A (Schering Corp) Chemical_Formula

C860H1353N229O255S9

Intron A (Schering Corp) RX_link

http://www.rxlist.com/cgi/generic2/ribav.htm

Intron A (Schering Corp) fda sheet

Intron A (Schering Corp) msds (material safety sheet)

Intron A (Schering Corp) Synthesis Reference

No information avaliable

Intron A (Schering Corp) Molecular Weight

19269.1

Intron A (Schering Corp) Melting Point

61 oC (Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999))

Intron A (Schering Corp) H2O Solubility

No information avaliable

Intron A (Schering Corp) State

Liquid

Intron A (Schering Corp) LogP

-0.339

Intron A (Schering Corp) Dosage Forms

Solution (Injection); Powder for Injection

Intron A (Schering Corp) Indication

For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma

Intron A (Schering Corp) Pharmacology

Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.

Intron A (Schering Corp) Absorption

No information avaliable

Intron A (Schering Corp) side effects and Toxicity

No information avaliable

Intron A (Schering Corp) Patient Information

BIOD00066.html

Intron A (Schering Corp) Organisms Affected

No information avaliable